Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 3, 2012, Pages 294-299

  Nakagawa, Fumiyo ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV; Treatment experienced patients; Triple class failure; Virologic failure

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; EUROPE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE; TREND STUDY;

ADULT; ANTI-HIV AGENTS; EUROPE; FEMALE; HIV; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PREVALENCE; RNA, VIRAL;

EID: 84859785732     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823fe66b     Document Type: Article

References (27)

1. BG Gazzard on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008; 9: 563-608.
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection. 2010 recommendations of the international AIDS society- USA panel. JAMA. 2010; 304: 321-333.
3. Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ. 2005; 330: 695.
4. Lampe FC, Smith CJ, Madge S, et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med. 2007; 167: 692-700. (Pubitemid 46598462)
5. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999; 353: 863-868. (Pubitemid 29126872)
6. Chaix ML, Descamps D, Wirden M, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS. 2009; 23: 717-724.
7. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003; 17: 1741-1751. (Pubitemid 37000092)
8. Martin-Carbonero L, Gil P, Garcia-Benayas T, et al. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients. AIDS Res Hum Retroviruses. 2006; 22: 1231-1235. (Pubitemid 46095239)
9. Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009; 49: 1582-1590.
10. Geretti AM, Smith C, Haberl A, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008; 13: 927-936.
11. Clumeck N, Pozniak A, Raffi F, et al. and the EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008; 9: 65-71. (Pubitemid 351228129)
12. The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med. 2010; 170: 410-419.
13. Gatell JM, Katlama C, Grinsztejn B, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J Acquir Immune Defic Syndr. 2010; 53: 456-463.
14. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003; 348: 2186-2195. (Pubitemid 36618129)
15. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005; 49: 4721-4732. (Pubitemid 41552605)
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. January 10, 2011: 1-166. Available at: http: //www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed October 14, 2011.
17. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004; 364: 51-62.
18. Costagliola D, Potard V, Duvivier C, et al. Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. Antivir Ther. 2005; 10: 563-573. (Pubitemid 41059204)
19. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Response to combination antiretroviral therapy: variation by age. AIDS. 2008; 22: 1463-1473.
20. The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet. 2011; 377: 1580-1587.
21. Lodwick RK, Smith CJ, Youle M, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS. 2008; 22: 1039-1046. (Pubitemid 351769742)
22. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS society-USA Panel. Clin Infect Dis. 2008; 47: 266-285. (Pubitemid 351920631)
23. Mocroft A, Ledergerber B, Viard JP, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA study group. J Infect Dis. 2004; 190: 1947-1956. (Pubitemid 39564700)
24. Mocroft A, Horban A, Clotet B, et al. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. HIV Med. 2008; 9: 41-46.
25. Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS. 2005; 19: 815-822. (Pubitemid 40834752)
26. Bansi L, Sabin C, Delpech V, et al. Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med. 2010; 11: 432-438.
27. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol. 2002; 76: 1753-1761. (Pubitemid 34094622)